Loading...
Market
Next BARDA funding recipient for vaccine development?
2
Resolution / Starting Odds
GeoVax • 25%
Moderna • 25%
Pfizer • 25%
Johnson & Johnson • 25%
BARDA funding announcements
Story
GeoVax and Moderna Receive $45M and $176M BARDA Funding for Vaccine Development
Jul 2, 2024, 11:02 AM
GeoVax Labs has advanced its COVID-19 vaccine development with up to $45 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). The funding is part of BARDA's Project NextGen initiative, which has a total of $4.7 billion at its disposal. So far, BARDA has awarded approximately 55% of this amount, with nearly $1.9 billion allocated to new COVID-19 vaccines. Since 2023, BARDA has awarded $2.58 billion in grants, with 73% of the funding directed towards vaccine development. BARDA Director Gary Disbrow highlighted the focus on immunocompromised populations. Additionally, Moderna has received $176 million from the US government to accelerate the development of a pandemic influenza mRNA vaccine, amid concerns over bird flu.
View original story
Similar markets
GSK • 25%
Sanofi • 25%
CSL • 25%
Equal distribution • 25%
Pfizer • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
GSK • 25%
Sanofi • 25%
CSL's Seqirus • 25%
None • 25%
Moderna • 25%
Sinergium Biotech • 25%
Pfizer • 25%
Other • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Sanofi • 25%
Other • 25%
Government grants • 25%
Private donations • 25%
Pharmaceutical companies • 25%
International organizations • 25%
Company X • 25%
Company Y • 25%
Company Z • 25%
Other • 25%
GSK • 25%
Sanofi • 25%
CSL • 25%
None by deadline • 25%
Pathogen A • 25%
Pathogen B • 25%
Pathogen C • 25%
Other • 25%
Moderna • 25%
Sinergium Biotech • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%